Insights, guides & briefings.
Working papers from our senior advisors on cross-border structuring, banking, licensing, mobility and tax. Long-form guides for the topics that repay careful reading; short briefings when the news moves.
Tier-by-tier diagrams of holding stacks, funds, trusts, licensed entities and asset vehicles — with the tax drivers and the failure points.
Browse the library →The brief, the structure we built, the sequence of steps, the timeline and the fee model — real files, identifying detail removed.
Read the files →Results
Stock Options Across Borders: The Tax Trap Nobody Flags at Grant
Options granted in one country and vested after a relocation can trigger tax in both. Here's why grant-date paperwork rarely accounts for it.
BVI or Cayman in 2026: a practical comparison, not a brochure
Both are stable, English-law, zero-tax jurisdictions with strong professional infrastructure — and they are not interchangeable. This guide compares the BVI and the Cayman Islands on the criteria that actually decide the answer: use case, cost, banking, funds, substance and exit.
Launching a fund in H2 2026: vehicle, domicile and the cost curve
Sub-$50m first-time funds are being squeezed from both ends — investor due diligence has institutionalised while running costs have risen. This briefing sets out which vehicles still work at what size, how Cayman, Luxembourg and ADGM compare in practice, and when a fund is the wrong answer entirely.
Cayman fund substance: field notes from 2025 filings
Cayman's economic-substance regime is no longer a form-filling exercise. TIA is asking pointed questions about board composition, expenditure, decision-making location and outsourced services — and funds that answered on autopilot are now being asked to prove it. These are the field notes from the 2025 filing cycle: what regulators actually pushed back on, and how to prepare the next return.
Every insight starts as a real client file.
If a piece here maps to your situation, the fastest next step is an advisor call — written diagnosis in five business days, fixed-fee from the first line.